KR920016448A - 피페리딘 유도체 - Google Patents

피페리딘 유도체 Download PDF

Info

Publication number
KR920016448A
KR920016448A KR1019920002533A KR920002533A KR920016448A KR 920016448 A KR920016448 A KR 920016448A KR 1019920002533 A KR1019920002533 A KR 1019920002533A KR 920002533 A KR920002533 A KR 920002533A KR 920016448 A KR920016448 A KR 920016448A
Authority
KR
South Korea
Prior art keywords
alkyl
group
compound
formula
oxygen
Prior art date
Application number
KR1019920002533A
Other languages
English (en)
Other versions
KR100196985B1 (ko
Inventor
하루히코 기쿠치
히로아키 사토
도시오 가츠로
고이치로 하기와라
도루 하야카와
세츠코 미노
Original Assignee
쇼다 오사무
닛신 세이훈 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쇼다 오사무, 닛신 세이훈 가부시키가이샤 filed Critical 쇼다 오사무
Publication of KR920016448A publication Critical patent/KR920016448A/ko
Application granted granted Critical
Publication of KR100196985B1 publication Critical patent/KR100196985B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

피페리딘 유도체.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(I)의 화합물 또는 이의 생리학적으로 허용가능한 염 또는 4급 암모늄염.
    상기식에서, A는
    중에서 선택되고, R1및 R2는 동일하거나 상이할 수 있고 각각은 수소원자, C1-C6알킬, 그룹, 페닐 그룹 또는 아릴(C1-C4)알킬 그룹이고, R3는 C1-C6알킬이며, R4는 수소원자,C1-C6알킬그룹, 페닐그룹 또는 아릴 (C1-C4)알킬그룹이고, R5,R6및 R7은 동일하거나 상이할 수 있고 각각은 수소원자, 아미노그룹, 할로겐원자, C1-C4알콕시 그룹 또는 프탈아미드 그룹이며, X는 산소 도는 NH이다.
  2. 제1항에 있어서, A는 일반식(a)의 그룹이고, R1및R2는 독립적으로 수소 또는 C1-C4알킬이며, R3는 C1-C4알킬이고, X는 산소인 화합물.
  3. 제1항에 있어서 A는 R4가C1-C4알킬인 일반식(b)의 그룹이고, R1및R2는 독립적으로 수소 또는 C1-C4알킬이며, R3는 C1-C4알킬이고, X는 산소인 화합물.
  4. 제1항에 있어서, A가 일반식(c)의 그룹이고, R1및R2는 독립적으로 수소 또는 C1-C4알킬이며, R3는 C1-C4알킬이고, X는 산소인 화합물.
  5. 제1항에 있어서, A가 일반식(d)의 그룹이고, R1및R2는 독립적으로 수소 또는 C1-C4알킬이며, R3는 C1-C4알킬이고, X는 산소인 화합물.
  6. 제1항에 있어서, A가 R5, R6및 R7이 독립적으로 수소, 아미노 할로겐 프탈이미드의 C1-C4알콕시인 일반 식 (e)의 그룹이고, R1및R2는 독립적으로 수소 또는 C1-C4알킬이며, R3가 C1-C4알킬이고, X는 산소인 화합물.
  7. 제1항에 있어서, A가 R4가 수소인 일반식(f)의 그룹이고, R1및R2는 독립적으로 수소 또는 C1-C4알킬이며, R3는 C1-C4알킬이고, X가 NH인 화합물.
  8. 활성성분으로서 제1항에서 정의된 일반식(I)의 화합물 또는 이의 생리학적으로 허용 가능한 염 또는 4급 암모늄염 하나 이상과 함께 하나 이상의 생리학적으로 허용 가능한 담체 또는 부형제를 포함하는 5-HT3수용체에서의 5-HT의 선택적 길항제로서 사용하기 위한 약제학적 조성물.
  9. 일반식(Ⅱ)의 화합물 또는 이의 반응성 유도체를 일반식(Ⅲ)의 화합물과 반응시키고, 경우에 따라, 유리염기 형태의 생성된 화합물을 이의 생리학적으로 허용 가능한 염 또는 4급 암모늄염으로 전환시킴을 특징으로 하여 일반식(I)의 화합물 또는 이의 생리학적으로 허용 가능한 염 또는 4급 암모늄염을 제조하는 방법.
    상기 식에서, R1및 R2는 동일하거나 상이할 수 있고 각각은 수소원자 C1-C6알킬그룹, 페닐그룹 또는 아릴(C1-C4)알킬그룹이고, R3는 C1-C6알킬그룹이며, R4는 수소원자 C1-C6알킬그룹, 페닐그룹 또는 아릴(C1-C4)알킬그룹이고, R5,R6및 R7은 동일하거나 상이할 수 있고 각각은 수소원자, 아미노그룹, 할로겐원자, C1-C4알콕시 그룹 또는 프탈이미드 그룹이며,X는 산소 또는 NH이고, A는 제1항에서 정의한 바와 동일하다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920002533A 1991-02-20 1992-02-20 피페리딘 유도체 KR100196985B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3045632A JP3026845B2 (ja) 1991-02-20 1991-02-20 ピペリジン誘導体
JP91-045632 1991-02-20

Publications (2)

Publication Number Publication Date
KR920016448A true KR920016448A (ko) 1992-09-24
KR100196985B1 KR100196985B1 (ko) 1999-06-15

Family

ID=12724744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920002533A KR100196985B1 (ko) 1991-02-20 1992-02-20 피페리딘 유도체

Country Status (6)

Country Link
US (1) US5246945A (ko)
EP (1) EP0499995B1 (ko)
JP (1) JP3026845B2 (ko)
KR (1) KR100196985B1 (ko)
CA (1) CA2060965A1 (ko)
DE (1) DE69216260T2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502273A (ja) * 1992-10-13 1996-03-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ▲下４▼レセプターアンタゴニスト用複素環式エステルまたはアミド
FR2705343B1 (fr) * 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
EP0823423B1 (en) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
RU2608611C2 (ru) 2009-11-05 2017-01-23 Юниверсити Оф Нотр Дам Дю Лак СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
IL257743B (en) 2015-09-17 2022-08-01 Marvin J Miller Heterocyclic compounds containing benzyl amine and preparations useful against mycobacterial inflammation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342826A (en) * 1964-01-13 1967-09-19 Ile De France Heterocyclic aminoalkyl benzamides
FR2313935A1 (fr) * 1975-06-10 1977-01-07 Ile De France Nouveaux benzamides substitues, leurs derives et leur procede de preparation
FR2155927A1 (en) * 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
US4310532A (en) * 1980-03-24 1982-01-12 The University Of Toledo Methods and piperidinyl-alkyl-benzamide composition for inhibiting H2 histamine receptors
CA1220141A (en) * 1981-06-13 1987-04-07 John R. Fozard Treatment of migraine with tropyl benzoate derivatives
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
US4486441A (en) * 1982-12-03 1984-12-04 Merrell Toraude Et Compagnie Pseudotropyl halogeno-benzoates and their use in migraine treatment
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
ES2059491T3 (es) * 1987-06-29 1994-11-16 Duphar Int Res Derivados de indol con anillos condensados.
GB8720693D0 (en) * 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
IT1231413B (it) * 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
CA2030051C (en) * 1989-11-17 2001-08-07 Haruhiko Kikuchi Indole derivatives

Also Published As

Publication number Publication date
JPH04266873A (ja) 1992-09-22
EP0499995B1 (en) 1997-01-02
DE69216260T2 (de) 1997-04-24
CA2060965A1 (en) 1992-08-21
EP0499995A3 (en) 1992-09-23
JP3026845B2 (ja) 2000-03-27
KR100196985B1 (ko) 1999-06-15
EP0499995A2 (en) 1992-08-26
DE69216260D1 (de) 1997-02-13
US5246945A (en) 1993-09-21

Similar Documents

Publication Publication Date Title
KR920002596A (ko) 아지비사이클로 유도체
KR850003402A (ko) 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법
HUP0102453A2 (hu) Adenozinszármazékok, alkalmazásuk és e vegyületeket tartalmazó gyógyászati készítmények
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
KR880013888A (ko) 신규 디티오아세탈 화합물, 그의 제조방법 및 이 화합물로 되는 제약 조성물
KR920016448A (ko) 피페리딘 유도체
KR910016697A (ko) 테트라히드로피리딘 유도체
KR900018006A (ko) 인간 신경 성장인자의 촉진용 페놀 유도체
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
KR900006296A (ko) 이미다졸린 유도체 및 그의 제조방법
KR900003163A (ko) 시클로헥산 유도체
KR960007592A (ko) 신규한 피롤로카바졸
TW360652B (en) Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
HUP9801386A2 (hu) Szerotonin 5-HT4 receptor parciális agonistáiként és antagonistáiként alkalmazható indazol-karboxamid-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
DK484787A (da) Bis-dioxopiperazin-derivater
KR850004585A (ko) 신규 아미노과니딘 유도체의 제조방법
KR900003177A (ko) 테트라시클릭계 우울증 치료제
ATE55057T1 (de) Zentralwirkende muskelrelaxante.
ATE170851T1 (de) Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten
KR930005999A (ko) 티오우레아 유도체 및 이를 함유하는 항균제 및 항궤양제
KR920002548A (ko) 피라졸리디논 cck 및 가스트린 길항물질 및 그의 약학 조성물
KR960702463A (ko) Dc-89 유도체[dc-89 derivative]
EP0251574A3 (en) Antifungal derivatives of n-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same
KR900006316A (ko) 벤조 헤테로 고리화합물 및 그 제조방법
DK0420224T3 (da) Anthihepatopatisk middel

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee